Albireo

99 articles about Albireo

• 

  Ipsen to Acquire Albireo for Rare Disease Portfolio

  1/9/2023

  Ipsen bolsters rare disease portfolio with acquisition of liver disease specialist Albireo.

• Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

  1/9/2023

  Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.

• Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 20, 2022

  12/20/2022

  Albireo Pharma, Inc. announced the grant to its newly appointed Chief Medical Officer, Paul D. Streck, M.D., of inducement restricted stock units to acquire 63,966 shares of Albireo’s common stock.

• Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

  12/6/2022

  Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopkinson, to the Enterprise Leadership Team and Board of Directors, respectively.

• Albireo to Participate in Jefferies London Healthcare Conference

  11/9/2022

  Albireo Pharma, Inc. today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.

• Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHAN

  10/13/2022

  Albireo Pharma, Inc. today announced the presentation of new data at the NASPGHAN Annual Meeting being held in Orlando, Florida from October 12-15, 2022.

• 

  Albireo Drug Makes "Profound" Difference in Rare Alagille Syndrome

  10/11/2022

  Albireo Pharma reported dazzling Phase III ASSERT data of Bylvay for Alagille syndrome (ALGS). The company is headed to U.S. and European regulators with expectations of regulatory filings in Q1 of 2023.

• Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

  10/5/2022

  Albireo Pharma, Inc. today announced the presentation of data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2022, being held November 4 – 8, 2022 in Washington, D.C.

• Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel

  8/16/2022

  Medison Pharma announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in Canada and Israel.

• Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

  8/3/2022

  Albireo Pharma, Inc. today announced participation in the 2022 Wedbush PacGrow Healthcare Conference August 9-10, 2022.

• Albireo to Present at the William Blair Biotech Focus Conference 2022

  6/30/2022

  Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biotech Focus Conference July 12-13, 2022.

• Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

  6/23/2022

  New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay ® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic parameters.

• Albireo to Present New Data at the EASL International Liver Congress™ 2022

  6/8/2022

  Albireo Pharma, Inc. today announced the presentation of seven abstracts/posters at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, being held June 22 – 26 in London.

• Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN

  6/7/2022

  Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) .

• 

  Clinical Catch-Up: 3's the Charm for Pfizer-BioNTech Vaccine in Kids & More

  5/30/2022

  A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.

• Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022

  5/23/2022

  Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that it presented analyses of its pivotal PEDFIC 1 and PEDFIC 2 studies which evaluated Bylvay for the treatment of progressive familial intrahepatic cholestasis (PFIC), at the Digestive Disease Week Annual Meeting held May 21-24, 2022.

• NICE Recommends Albireo’s Bylvay® (odevixibat) for All PFIC Types

  2/22/2022

  Albireo Pharma, Inc. announced that the National Institute for Health and Care Excellence has issued guidance that recommends Bylvay for the treatment of all types of progressive familial intrahepatic cholestasis in people aged six months and older.

• Albireo Announces Changes to R&D Organization

  12/9/2021

  Albireo Pharma, Inc. today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company.

• Albireo to Present at Upcoming Investor Conferences - Nov 10, 2021

  11/10/2021

  Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company’s management team will be presenting at the following investor conferences:

• Albireo Reports Q3 Financial Results and Business Update

  11/4/2021

  Albireo Pharma, Inc. today provided a business update and reported financial results for the third quarter ended September 30, 2021.